Insider Transactions in Q2 2025 at Kala Pharmaceuticals, Inc. (KALA)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2025
|
Mark T Iwicki |
SELL
Open market or private sale
|
Direct |
13,227
-4.87%
|
$52,908
$4.01 P/Share
|
|
Jun 24
2025
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
5,251
-5.97%
|
$21,004
$4.01 P/Share
|
|
Jun 24
2025
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
4,058
-4.62%
|
$16,232
$4.01 P/Share
|
|
Jun 24
2025
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,631
-5.52%
|
$14,524
$4.01 P/Share
|
|
Jun 24
2025
|
Darius Kharabi CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
4,511
-6.73%
|
$18,044
$4.01 P/Share
|
|
Jun 15
2025
|
Andrew I Koven |
BUY
Grant, award, or other acquisition
|
Direct |
3,050
+15.23%
|
-
|
|
Jun 15
2025
|
C. Daniel Myers |
BUY
Grant, award, or other acquisition
|
Direct |
2,450
+19.1%
|
-
|
|
Jun 15
2025
|
Gregory D Perry |
BUY
Grant, award, or other acquisition
|
Direct |
2,450
+15.51%
|
-
|
|
Jun 15
2025
|
Marjan Farid |
BUY
Grant, award, or other acquisition
|
Direct |
2,450
+19.3%
|
-
|
|
Jun 15
2025
|
Mark T Iwicki |
BUY
Grant, award, or other acquisition
|
Direct |
2,450
+0.89%
|
-
|
|
Jun 15
2025
|
Howard B Rosen |
BUY
Grant, award, or other acquisition
|
Direct |
2,450
+13.11%
|
-
|
|
Jun 03
2025
|
Mark T Iwicki |
BUY
Open market or private sale
|
Direct |
10,866
+3.88%
|
$32,598
$3.74 P/Share
|
|
Jun 03
2025
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
3,687
-4.02%
|
$11,061
$3.74 P/Share
|
|
Jun 03
2025
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
3,390
-3.72%
|
$10,170
$3.74 P/Share
|
|
Jun 03
2025
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,850
-4.16%
|
$8,550
$3.74 P/Share
|
|
Jun 03
2025
|
Darius Kharabi CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
730
-1.08%
|
$2,190
$3.74 P/Share
|